CO7111276A2 - Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met - Google Patents

Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met

Info

Publication number
CO7111276A2
CO7111276A2 CO14238774A CO14238774A CO7111276A2 CO 7111276 A2 CO7111276 A2 CO 7111276A2 CO 14238774 A CO14238774 A CO 14238774A CO 14238774 A CO14238774 A CO 14238774A CO 7111276 A2 CO7111276 A2 CO 7111276A2
Authority
CO
Colombia
Prior art keywords
disubstituted
pyridine
modulators
compounds
triaolo
Prior art date
Application number
CO14238774A
Other languages
English (en)
Spanish (es)
Inventor
Swaroop Kumar V S Vakkalanka
Dhanapalan Nagarathnam
Srikant Viswanadha
Meyyappan Muthuppalaniappan
Govindarajulu Babu
Prashant Kashinath Bhavar
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48093046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7111276(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of CO7111276A2 publication Critical patent/CO7111276A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14238774A 2012-03-30 2014-10-28 Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met CO7111276A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1262CH2012 2012-03-30

Publications (1)

Publication Number Publication Date
CO7111276A2 true CO7111276A2 (es) 2014-11-10

Family

ID=48093046

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14238774A CO7111276A2 (es) 2012-03-30 2014-10-28 Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met

Country Status (21)

Country Link
US (3) US9815831B2 (ru)
EP (1) EP2831073B1 (ru)
JP (1) JP6192708B2 (ru)
KR (2) KR20140144726A (ru)
CN (2) CN104321322A (ru)
AP (1) AP3908A (ru)
AU (1) AU2013239398B2 (ru)
BR (1) BR112014024251A8 (ru)
CA (1) CA2865719C (ru)
CL (1) CL2014002604A1 (ru)
CO (1) CO7111276A2 (ru)
EA (1) EA026412B1 (ru)
ES (1) ES2856848T3 (ru)
HK (1) HK1204612A1 (ru)
IL (1) IL234513B (ru)
MX (1) MX359888B (ru)
MY (1) MY169268A (ru)
NZ (1) NZ629499A (ru)
PH (1) PH12014502166A1 (ru)
SG (1) SG11201406185WA (ru)
WO (1) WO2013144737A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2013144737A2 (en) * 2012-03-30 2013-10-03 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
CA2993018A1 (en) 2015-07-20 2017-01-26 Genzyme Corporation Colony stimulating factor-1 receptor (csf-1r) inhibitors
CN107573340B (zh) * 2017-10-23 2020-11-24 江西科技师范大学 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
AU2022264784A1 (en) * 2021-04-29 2023-11-16 Amgen Inc. Heterocyclic compounds and methods of use
CN114031562A (zh) * 2021-10-31 2022-02-11 南京碳硅人工智能生物医药技术研究院有限公司 一种具有抗肿瘤的吡啶衍生物的工艺优化
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
CN1225639A (zh) 1996-07-18 1999-08-11 美国辉瑞有限公司 基于次膦酸酯的基质金属蛋白酶抑制剂
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ID22799A (id) 1997-02-03 1999-12-09 Pfizer Prod Inc Turunan-turunan asam arilsulfonilamino hidroksamat
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EE04852B1 (et) 1999-02-22 2007-06-15 Gesellschaft Fuer Biotechnologische Forschung Mbh C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
AU2004258071A1 (en) 2003-06-19 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants of human taste receptor genes
EP1660487B1 (en) 2003-08-15 2008-03-19 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
US7169800B2 (en) 2003-09-24 2007-01-30 Vertex Pharmaceuticals Incorporated Imidazole compositions useful as inhibitors of protein kinases
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
KR100859891B1 (ko) 2004-08-26 2008-09-23 화이자 인코포레이티드 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
ES2354824T3 (es) 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
WO2007111904A2 (en) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
US8481538B2 (en) 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
AU2007309237B2 (en) 2006-10-23 2012-03-22 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
WO2008054702A1 (en) 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
WO2008060866A1 (en) 2006-11-14 2008-05-22 Smithkline Beecham Corporation Novel compounds
WO2008078085A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Method
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
CA2679602A1 (en) 2007-02-23 2008-08-28 Eisai R&D Management Co., Ltd. Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
EP2217595A1 (en) 2007-10-29 2010-08-18 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
CN101910165A (zh) 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的噻唑衍生物
JP2011502160A (ja) 2007-10-29 2011-01-20 シェーリング コーポレイション プロテインキナーゼ阻害剤としての複素環式尿素およびチオ尿素誘導体ならびにそれらの使用方法
CA2703979A1 (en) 2007-10-29 2009-05-07 Schering Corporation Heterocyclic ether and thioether derivatives and methods of use thereof
EP2276346B1 (en) * 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
DK3511330T3 (da) * 2009-12-31 2020-12-21 Hutchison Medipharma Ltd Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer
CN102127096A (zh) 2009-12-31 2011-07-20 和记黄埔医药（上海）有限公司 三氮唑并吡啶和三氮唑并吡嗪化合物及其组合物和应用
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2013144737A2 (en) * 2012-03-30 2013-10-03 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
US9887269B2 (en) * 2015-11-30 2018-02-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-gate device and method of fabrication thereof

Also Published As

Publication number Publication date
US20150057309A1 (en) 2015-02-26
EA201491520A1 (ru) 2015-03-31
AU2013239398A1 (en) 2014-09-18
PH12014502166B1 (en) 2014-12-10
CA2865719C (en) 2020-09-22
HK1204612A1 (en) 2015-11-27
CN107082779A (zh) 2017-08-22
EP2831073B1 (en) 2020-12-09
CN104321322A (zh) 2015-01-28
IL234513B (en) 2019-08-29
KR20140144726A (ko) 2014-12-19
AP2014007966A0 (en) 2014-09-30
MX359888B (es) 2018-10-15
SG11201406185WA (en) 2014-11-27
WO2013144737A3 (en) 2013-12-05
MX2014011750A (es) 2015-10-22
US20180072721A1 (en) 2018-03-15
EP2831073A2 (en) 2015-02-04
WO2013144737A2 (en) 2013-10-03
BR112014024251A8 (pt) 2018-01-23
EA026412B1 (ru) 2017-04-28
US11066402B2 (en) 2021-07-20
AU2013239398B2 (en) 2017-09-07
PH12014502166A1 (en) 2014-12-10
KR20200013111A (ko) 2020-02-05
MY169268A (en) 2019-03-20
JP6192708B2 (ja) 2017-09-06
JP2015511629A (ja) 2015-04-20
US20210371416A1 (en) 2021-12-02
KR102164317B1 (ko) 2020-10-13
AP3908A (en) 2016-11-24
CL2014002604A1 (es) 2015-04-10
ES2856848T3 (es) 2021-09-28
US9815831B2 (en) 2017-11-14
CA2865719A1 (en) 2013-10-03
NZ629499A (en) 2016-05-27

Similar Documents

Publication Publication Date Title
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CO6551721A2 (es) Moduladores de cinasa novedosos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CO7170166A2 (es) Inhibidores de pi3k delta selectivos
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2012002035A1 (es) Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
CO2018005354A2 (es) Derivados novedosos de diamino piridina
BR112016004904A8 (pt) moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr
BR112017011335A2 (pt) compostos de 4h-pirido[1,2-a]pirimidin-4-ona
EA202092370A1 (ru) Новые модуляторы киназ
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ